The broad objective of this proposal for continuation of R01CA79804 is to elucidate the role of MDM2 on cell proliferation and tumorigenesis. MDM2 has p53-dependent and p53-independent oncogenic functions. While MDM2 p53-dependent function has been intensively studied, the p53-independent functions of MDM2 are not well understood. This application focuses on MDM2-mediated regulation on retinoblastoma protein (Rb). Work from us and others showed that MDM2 interacts with Rb and promotes S-phase entry independent of p53. We recently showed that MDM2 binds to the Rb C-pocket and disrupts Rb-E2F interaction. Furthermore, we demonstrated that activation of MDM2 promotes Rb protein degradation in a proteasome-dependent pathway whereas knockdown of MDM2 results in accumulation of Rb and cell cycle arrest. In this continuation application, we hypothesize that MDM2-mediated Rb destabilization critically contributes to pathological progress of tumorigenesis.
Specific Aim 1 is to elucidate the molecular mechanism by which MDM2 regulates Rb.
Specific Aim 2 is to investigate the roles of MDMx and tumor suppressor protein ARF in modulation of MDM2-Rb and Specific aim 3 is to examine the role of MDM2-Rb in tumorigenesis in vivo. Information obtained from this study will provide considerable insight of the biological and pathological role of MDM-Rb in cell proliferation and human tumorigenesis. Inactivation of retinoblastoma protein (Rb) is critical in human cancer development. Rb can be inactivated by gene mutations and by abnormal hyperphosphorylation. How Rb is degraded is poorly understood. Work from us and others demonstrates that the cellular oncoprotein MDM2 also targets and promotes Rb protein degradation. This study is aimed at elucidating the role of he MDM2-Rb pathway in human tumorigenesis. Information obtained from this study would further our understanding of human carcinogenesis and help identify therapeutic drug targets for cancer prevention and treatment.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Cancer Molecular Pathobiology Study Section (CAMP)
Program Officer
Watson, Joanna M
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Boston University
Schools of Medicine
United States
Zip Code
Walsh, Erica M; Niu, MengMeng; Bergholz, Johann et al. (2015) Nutlin-3 down-regulates retinoblastoma protein expression and inhibits muscle cell differentiation. Biochem Biophys Res Commun 461:293-9
Tong, Y; Ying, H; Liu, R et al. (2015) Pin1 inhibits PP2A-mediated Rb dephosphorylation in regulation of cell cycle and S-phase DNA damage. Cell Death Dis 6:e1640
Wu, J; Liang, S; Bergholz, J et al. (2014) ?Np63? activates CD82 metastasis suppressor to inhibit cancer cell invasion. Cell Death Dis 5:e1280
Tran, Duc; Bergholz, Johann; Zhang, Haibo et al. (2014) Insulin-like growth factor-1 regulates the SIRT1-p53 pathway in cellular senescence. Aging Cell 13:669-78
Bergholz, J; Zhang, Y; Wu, J et al. (2014) ?Np63? regulates Erk signaling via MKP3 to inhibit cancer metastasis. Oncogene 33:212-24
Du, Wei; Yi, Yong; Zhang, Haibo et al. (2013) Rapamycin inhibits IGF-1-mediated up-regulation of MDM2 and sensitizes cancer cells to chemotherapy. PLoS One 8:e63179
Wu, Junfeng; Bergholz, Johann; Lu, Jinin et al. (2010) TAp63 is a transcriptional target of NF-kappaB. J Cell Biochem 109:702-10
Du, Wei; Wu, Junfeng; Walsh, Erica M et al. (2009) Nutlin-3 affects expression and function of retinoblastoma protein: role of retinoblastoma protein in cellular response to nutlin-3. J Biol Chem 284:26315-21
Qiu, W; Wu, J; Walsh, E M et al. (2008) Retinoblastoma protein modulates gankyrin-MDM2 in regulation of p53 stability and chemosensitivity in cancer cells. Oncogene 27:4034-43
Murray, Stephen A; Yang, Shi; Demicco, Elizabeth et al. (2005) Increased expression of MDM2, cyclin D1, and p27Kip1 in carcinogen-induced rat mammary tumors. J Cell Biochem 95:875-84

Showing the most recent 10 out of 15 publications